MacroGenics Inc (MGNX) Stock AnalysisMGNXMacroGenics Inc

MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MacroGenics Inc appears to be a good buy right now due to its current price of $4.13, which is significantly below the analyst price targets of $6 and $9. The stock has shown a year-to-date change of +156.52%, indicating strong momentum. However, the main risk is its negative net income margin of -212.12% reported in Q2 2026, which highlights ongoing financial challenges. Overall, the combination of positive analyst sentiment and strong recent performance suggests a favorable buying opportunity.

11 analysts cover MGNX: 9 rate it Buy, 2 Hold and 0 Sell. The average price target is 3.00.